ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Proxy vote

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Apr 14, 2022 1:07am

217 Views

Post# 34602728

Proxy vote

For those of you who are just getting your proxies, yes you sheep. Vote for Cashman and withhold for everyone else Lots of dead weight on this board and it's long needed a management change. Wyman , Gregory, Williams and Kirwin have done nothing to create shareholder value and are poor decision makers.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China